论文部分内容阅读
目的:观察人尿激肽原酶(尤瑞克林)在急性脑梗死治疗中的有效性和安全性。方法:对30例急性脑梗死患者给予单用尤瑞克林治疗2周,治疗前后以NIHSS、mRS量表评价疗效。结果:治疗后30例患者NIHSS评分低于治疗前,差异有统计学意义(P<0.05);mRS评分低于治疗前,有显著性差异(P<0.01)。基本痊愈4例,显著进步16例,进步5例,无变化4例,恶化1例,总显效(基本痊愈+显著进步)20例。出现恶心呕吐者2例,转氨酶增高者1例,所有治疗未见血压明显下降(下降>30%)。血尿常规、血糖、血脂、肾功能未见明显变化。结论:应用尤瑞克林治疗急性脑梗死安全且临床疗效肯定。
Objective: To observe the efficacy and safety of human urokinase (urelin) in the treatment of acute cerebral infarction. Methods: Thirty patients with acute cerebral infarction were treated with urelin alone for 2 weeks. The therapeutic effect was evaluated by NIHSS and mRS before and after treatment. Results: The NIHSS scores of 30 patients after treatment were lower than those before treatment (P <0.05). The mRS scores were lower than those before treatment (P <0.01). There were 4 cases of complete recovery, 16 cases of significant improvement, 5 cases of improvement, 4 cases of no change, 1 case of deterioration, and 20 cases of total effective (basic recovery + significant improvement). 2 cases of nausea and vomiting, 1 case of elevated aminotransferase, no significant decrease in blood pressure (drop> 30%) in all treatments. Hematuria routine, blood glucose, blood lipids, no significant changes in renal function. Conclusion: The application of ureclin in the treatment of acute cerebral infarction is safe and the clinical curative effect is definite.